Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $367,609 | 128 | 57.2% |
| Travel and Lodging | $157,178 | 106 | 24.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,497 | 14 | 8.9% |
| Honoraria | $51,645 | 14 | 8.0% |
| Food and Beverage | $9,060 | 78 | 1.4% |
| Education | $83.80 | 6 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $129,713 | 72 | $0 (2023) |
| Eli Lilly and Company | $114,450 | 75 | $0 (2022) |
| ABBVIE INC. | $89,080 | 70 | $0 (2024) |
| PFIZER INC. | $83,694 | 22 | $0 (2024) |
| H. Lundbeck A S | $82,262 | 29 | $0 (2023) |
| Lilly USA, LLC | $45,260 | 15 | $0 (2022) |
| Allergan, Inc. | $41,491 | 21 | $0 (2021) |
| Lundbeck LLC | $15,441 | 9 | $0 (2023) |
| Ipsen Innovation | $14,413 | 8 | $0 (2018) |
| Biohaven Pharmaceuticals, Inc. | $13,946 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,576 | 26 | PFIZER INC. ($47,590) |
| 2023 | $71,210 | 33 | PFIZER INC. ($35,993) |
| 2022 | $166,041 | 83 | H. Lundbeck A S ($75,518) |
| 2021 | $62,285 | 25 | Lilly USA, LLC ($16,675) |
| 2020 | $52,475 | 31 | Eli Lilly and Company ($31,508) |
| 2019 | $93,280 | 57 | Eli Lilly and Company ($36,322) |
| 2018 | $86,959 | 53 | Amgen Inc. ($54,640) |
| 2017 | $49,247 | 38 | Eli Lilly and Company ($22,813) |
All Payment Transactions
346 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | QULIPTA (Drug) | Consulting Fee | Cash or cash equivalent | $5,175.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/21/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $4,509.00 | General |
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $130.85 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/12/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $345.00 | General |
| 10/04/2024 | ABBVIE INC. | UBRELVY (Drug) | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/05/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| 08/23/2024 | PFIZER INC. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $18,765.00 | General |
| Category: PAIN | ||||||
| 08/09/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,035.00 | General |
| 08/01/2024 | PFIZER INC. | NURTEC ODT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,830.00 | General |
| Category: PAIN | ||||||
| 08/01/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,035.00 | General |
| 08/01/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $517.50 | General |
| 07/10/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $517.50 | General |
| 06/14/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $121.91 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $48.82 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $229.89 | General |
| 05/29/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| 04/30/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: PAIN | ||||||
| 04/22/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/22/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/27/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $211.41 | General |
| Category: PAIN | ||||||
| 03/26/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PAIN | ||||||
| 03/18/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $3,426.58 | General |
| Category: PAIN | ||||||
| 03/18/2024 | PFIZER INC. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $463.82 | General |
| Category: PAIN | ||||||
| 03/18/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $133.87 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 14 | 14 | $19,040 | $2,426 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $19,040 | $2,426 | 12.7% |
About Dr. Peter Goadsby, MD
Dr. Peter Goadsby, MD is a Internal Medicine healthcare provider based in Los Agneles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164606943.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Goadsby, MD has received a total of $643,073 in payments from pharmaceutical and medical device companies, with $61,576 received in 2024. These payments were reported across 346 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($367,609).
As a Medicare-enrolled provider, Goadsby has provided services to 14 Medicare beneficiaries, totaling 14 services with total Medicare billing of $2,426. Data is available for 1 year (2021–2021), covering 1 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Neurology
- Location Los Agneles, CA
- Active Since 12/28/2007
- Last Updated 02/01/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164606943
Products in Payments
- VYEPTI (Biological) $97,703
- Aimovig (Biological) $97,284
- NURTEC ODT (Drug) $93,130
- UBRELVY (Drug) $29,861
- QULIPTA (Drug) $28,758
- EMGALITY (Drug) $27,060
- BOTOX (Biological) $21,267
- Dysport (Drug) $14,413
- ELYXYB - CELECOXIB (Drug) $3,000
- BOTOX THERAPEUTIC (Biological) $2,755
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $2,217
- Repatha (Biological) $1,750
- Product in Development (Device) $1,360
- Seglentis (Drug) $1,350
- ELYXYB (Drug) $1,200
- CARDIOFORM Septal Occluder (Device) $46.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.